The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19

Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19

(2022) Tim J. L. Smeets et al.   CLINICAL PHARMACOKINETICS

Acute kidney injury in patients with COVID-19 in the intensive care unit: evaluation of risk factors and mortality in a national cohort

(2022) Eirik Aasen Aukland et al.   BMJ Open

Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study

(2021) Brenda T Pun et al.   Lancet Respiratory Medicine

Sedation Usage in COVID-19 Acute Respiratory Distress Syndrome: A Multicenter Study

(2021) Natalie Tapaskar et al.   ANNALS OF PHARMACOTHERAPY

Clearance of Lormetazepam, Midazolam, and Their Conjugated Metabolites by Continuous Venovenous Hemofiltration During Prolonged Sedation in Critically Ill Patients With COVID‐19‐Associated Acute Respiratory Distress Syndrome

(2021) Kimberly N. Shudofsky et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Acute kidney injury in patients hospitalized with COVID-19

(2020) Jamie S. Hirsch et al.   KIDNEY INTERNATIONAL

Filter clotting with continuous renal replacement therapy in COVID-19

(2020) Paul Endres et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Effluent Volume in Continuous Renal Replacement Therapy Overestimates the Delivered Dose of Dialysis

(2010) R. Claure-Del Granado et al.   Clinical Journal of the American Society of Nephrology

Principles of antibacterial dosing in continuous renal replacement therapy

(2009) Gordon Choi et al.   CRITICAL CARE MEDICINE